메뉴 건너뛰기




Volumn 110, Issue 10, 2012, Pages 1408-1411

Prostate cancer treatment: The times they are a' changin'

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTIANDROGEN; CABAZITAXEL; DEGARELIX; DOCETAXEL; ENZALUTAMIDE; GONADORELIN DERIVATIVE; MITOXANTRONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

EID: 84868197612     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11441.x     Document Type: Note
Times cited : (2)

References (19)
  • 1
    • 79952260758 scopus 로고    scopus 로고
    • Improved survival prospects for patients with castration-resistant prostate cancer
    • Kirby R, Fitzpatrick JM,. Improved survival prospects for patients with castration-resistant prostate cancer. BJU Int 2011; 107: 697-700
    • (2011) BJU Int , vol.107 , pp. 697-700
    • Kirby, R.1    Fitzpatrick, J.M.2
  • 2
    • 75749098139 scopus 로고    scopus 로고
    • Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges
    • Glina S, Rivero MA, Morales A, Morgentaler A,. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. J Sex Med 2010; 7: 640-4
    • (2010) J Sex Med , vol.7 , pp. 640-644
    • Glina, S.1    Rivero, M.A.2    Morales, A.3    Morgentaler, A.4
  • 3
    • 84858212484 scopus 로고    scopus 로고
    • Prostate-cancer mortality at 11 years of follow-up
    • Schroder FH, Hugosson J, Roobol MJ, et al,. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90
    • (2012) N Engl J Med , vol.366 , pp. 981-990
    • Schroder, F.H.1    Hugosson, J.2    Roobol, M.J.3
  • 4
    • 84859645406 scopus 로고    scopus 로고
    • Active surveillance for favorable-risk prostate cancer: Background, patient selection, triggers for intervention, and outcomes
    • Klotz L,. Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Opin Urol 2012; 22: 222-30
    • (2012) Curr Opin Urol , vol.22 , pp. 222-230
    • Klotz, L.1
  • 5
    • 84862877628 scopus 로고    scopus 로고
    • Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial
    • Vickers A, Bennette C, Steineck G, et al,. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group Randomized Trial. Eur Urol 2012; 62: 204-9
    • (2012) Eur Urol , vol.62 , pp. 204-209
    • Vickers, A.1    Bennette, C.2    Steineck, G.3
  • 7
    • 78650257452 scopus 로고    scopus 로고
    • Retropubic, laparoscopic, and robot-assisted radical prostatectomy: A critical review of outcomes reported by high-volume centers
    • Coelho RF, Rocco B, Patel MB, et al,. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 2010; 24: 2003-15
    • (2010) J Endourol , vol.24 , pp. 2003-2015
    • Coelho, R.F.1    Rocco, B.2    Patel, M.B.3
  • 8
    • 84861576924 scopus 로고    scopus 로고
    • Focal therapy for localised unifocal and multifocal prostate cancer: A prospective development study
    • Ahmed H, Hindley R, Dickinson L, et al,. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13: 622-32
    • (2012) Lancet Oncol , vol.13 , pp. 622-632
    • Ahmed, H.1    Hindley, R.2    Dickinson, L.3
  • 9
    • 67650602865 scopus 로고    scopus 로고
    • High intensity focused ultrasound - Early experience and 2 year results
    • Challacombe B, Zakri R, Murphy D, Cahill D,. High intensity focused ultrasound-early experience and 2 year results. BJU Int 2009; 104: 200-4
    • (2009) BJU Int , vol.104 , pp. 200-204
    • Challacombe, B.1    Zakri, R.2    Murphy, D.3    Cahill, D.4
  • 11
    • 38349167518 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
    • Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
    • (2008) J Clin Oncol , vol.26 , pp. 242-245
    • Berthold, D.R.1    Pond, G.R.2    Soban, F.3    De Wit, R.4    Eisenberger, M.5    Tannock, I.F.6
  • 13
    • 77956542827 scopus 로고    scopus 로고
    • Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)
    • (Suppl.)
    • De Bono JS, Oudard S, Ozguroglu M, et al,. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). J Clin Oncol 2010; 28 (Suppl.): 4508
    • (2010) J Clin Oncol , vol.28 , pp. 4508
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 14
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
    • de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
    • (2010) Lancet , vol.376 , pp. 1147-1154
    • De Bono, J.S.1    Oudard, S.2    Ozguroglu, M.3
  • 15
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 16
    • 84865336863 scopus 로고    scopus 로고
    • Optimizing the care of patients with advanced prostate cancer in the UK: Current challenges and future opportunities
    • [Epub ahead of print]. DOI: 10.1111/j.1464-410X.2011.10886.x
    • Payne H, Bahl A, Mason M, Troup J, De Bono J,. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; [Epub ahead of print]. DOI: 10.1111/j.1464-410X. 2011.10886.x
    • (2012) BJU Int
    • Payne, H.1    Bahl, A.2    Mason, M.3    Troup, J.4    De Bono, J.5
  • 17
    • 77952105685 scopus 로고    scopus 로고
    • Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
    • Scher HI, Beer TM, Higano CS, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46
    • (2010) Lancet , vol.375 , pp. 1437-1446
    • Scher, H.I.1    Beer, T.M.2    Higano, C.S.3
  • 19
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff P, Higano C, Shore D, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-21
    • (2010) N Engl J Med , vol.363 , pp. 411-421
    • Kantoff, P.1    Higano, C.2    Shore, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.